Shares of Cempra Inc. plunged nearly 15% in extended trading on Thursday after the company announced that the FDA may not allow it to use the active product ingredient or API, manufactured at India-based Wockhardt Ltd. for approval and commercial supply of Solithromycin, suggesting a delay in the launch of the drug, if approved.
from RTT - Biotech http://ift.tt/2flWuA2
via IFTTT
No comments:
Post a Comment